| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1031452018 |
| P356 | DOI | 10.1054/BJOC.1999.0977 |
| P932 | PMC publication ID | 2363339 |
| P698 | PubMed publication ID | 10682679 |
| P5875 | ResearchGate publication ID | 12632176 |
| P50 | author | Adam Patterson | Q38324051 |
| Ian Stratford | Q56529169 | ||
| P2093 | author name string | A L Harris | |
| E C Chinje | |||
| M P Saunders | |||
| P2860 | cites work | SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours | Q35976983 |
| Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 | Q36431422 | ||
| Intermittent blood flow in a murine tumor: radiobiological effects | Q36481293 | ||
| Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) | Q64390275 | ||
| Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue | Q64445223 | ||
| Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical | Q68254687 | ||
| Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075) | Q70630698 | ||
| Alterations in expression of CYP1A1 and NADPH-cytochrome P450 reductase during lung tumor development in SWR/J mice | Q70908736 | ||
| Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia | Q72770316 | ||
| Enzymology of tirapazamine metabolism: a review | Q77356802 | ||
| Determinants of tumor blood flow: a review | Q39636842 | ||
| The experimental development of bioreductive drugs and their role in cancer therapy. | Q40848141 | ||
| Bioreductive drugs for cancer therapy: the search for tumor specificity | Q41033230 | ||
| Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity | Q41099312 | ||
| Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors | Q41213138 | ||
| Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. | Q41495379 | ||
| Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). | Q42261948 | ||
| Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. | Q43614988 | ||
| Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. | Q46863012 | ||
| The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). | Q50772616 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| cytotoxicity | Q246181 | ||
| cancer cell line | Q23058136 | ||
| P304 | page(s) | 651-656 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line | |
| P478 | volume | 82 |
| Q38714686 | A Near-Infrared, Wavelength-Shiftable, Turn-on Fluorescent Probe for the Detection and Imaging of Cancer Tumor Cells. |
| Q90501202 | Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia |
| Q37369324 | Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice |
| Q61813196 | Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials |
| Q39762897 | Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. |
| Q40412615 | The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. |
| Q34090988 | Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia |
| Q36729104 | Tumor hypoxia and targeted gene therapy |
Search more.